Volume 11, Number 8—August 2005
Dispatch
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Ran D. Balicer*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
, Michael Huerta*, Nadav Davidovitch*†, and Itamar Grotto*†
Table 1
Point estimate and range of values for selected model variables*
| Variable | Point estimate | Range |
|---|---|---|
| Overall attack rate, %† | 25 | 15–35 |
| Probability of pandemic (per year) | 3 | 1–10 |
| Adult workdays lost, by age, y | ||
| <1–≤18 | 3.7 | 2–5 |
| 19–64 | 4.9 | 3–7 |
| ≥65 | 0.5 | 0.25–2 |
| Average hospital stay (days) by age, y | ||
| <1–≤18 | 4.0 | 2–5 |
| 19–64 | 5.8 | 2–7 |
| ≥65 | 7.0 | 4-9 |
| Patients seeking medical care within 48 h, % | 80 | 70–90 |
| Efficacy of antiviral prophylaxis, % | ||
| Preexposure prophylaxis (50 days) | 71 | 57–85 |
| Postexposure prophylaxis (7 days) | 36 | 25–47 |
| Efficacy of antiviral therapy, % | ||
| Reduction in hospitalizations | 59 | 30–70 |
| Reduction in antimicrobial drug use |
63 |
40–80 |
| Reduction in lost workdays under treatment | 1 | 0.5–1.5 |
*Complete list and references available in online Appendix.
†Population attack rate was calculated by stratifying the population by age and risk and applying age- and risk-specific attack rates and ranges (Appendix).
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.